Table 2.

Univariable analysis of time to treatment failure and overall survival (Cox hazard model).

Variables	TTF			OS
	HR	95% CI	P	HR	95% CI	P
Age (≥ 65 vs. < 65 years)	1.16	0.79–1.70	0.454	1.27	0.81–1.98	0.295
ER (negative vs. positive)	1.09	0.72–1.67	0.678	1.02	0.63–1.66	0.929
Diagnosis (recurrence vs. advanced)	1.36	0.92–2.00	0.127	1.35	0.86–2.14	0.195
Metastatic sites (yes vs. no)
CNS	1.28	0.66–2.47	0.463	1.39	0.67–2.89	0.380
Bone	0.96	0.65–1.40	0.818	0.98	0.63–1.53	0.945
Lung	0.58	0.39–0.86	0.007	0.65	0.42–1.02	0.060
Pleura and/or lymphangiopathy	0.97	0.66–1.43	0.876	0.83	0.53–1.30	0.425
Lymph node	0.97	0.61–1.54	0.895	0.77	0.46–1.31	0.334
Liver	1.37	0.93–2.00	0.110	1.44	0.92–2.24	0.109
Soft tissue	0.76	0.51–1.14	0.184	0.92	0.59–1.45	0.729
Visceral metastasis (yes vs. no)	0.81	0.50–1.31	0.392	0.96	0.55–1.68	0.880
Number of metastatic sites (≥ 3 vs. < 3)	0.70	0.43–1.14	0.153	0.79	0.45–1.38	0.403
Prior (neo) adjuvant chemotherapy* (yes vs. no)	1.54	1.02–2.32	0.039	1.28	0.80–2.05	0.304
Disease-free interval (< 24 months vs. ≥ 24 months)	1.16	0.79–1.70	0.438	1.23	0.79–1.91	0.367
Number of previous chemotherapies (< 2 vs. ≥ 2)	0.90	0.57–1.41	0.644	0.46	0.28–0.75	0.002
Marker of systemic immunity
ALC > 1500/μL versus ALC ≤ 1500/μL	0.54	0.34–0.86	0.010	0.38	0.21–0.71	0.002
NLR ≤ 3 versus NLR > 3	0.59	0.40–0.87	0.007	0.54	0.35–0.84	0.006
PLR ≤ 300 versus PLR > 300	0.55	0.36–0.85	0.006	0.65	0.40–1.06	0.083
LMR > 3 versus LMR ≤ 3	0.66	0.45–0.97	0.034	0.58	0.37–0.90	0.016

ALC absolute lymphocyte count, CI confidence interval, CNS central nervous system, ER estrogen receptor, HR hazard ratio, LMR lymphocyte-to-monocyte ratio, NLR neutrophil-to-lymphocyte ratio, OS overall survival, PLR platelet-to-lymphocyte ratio, TTF time to treatment failure.

*Chemotherapy included anthracycline and/or taxane.